Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of follow-up
Late-breaking data presented in oral session at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium with same-day Publication in The Lancet
CheckMate -8HW previously demonstrated that Opdivo plus Yervoy reduced the risk of disease progression or death by 79% compared to investigator’s choice of chemotherapy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.